Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05583071 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Study acronym: MTR²
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revisedv6
  2. Eligibility criteria expanded, about 16 wordsv5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 6
    • Start date changed from estimate of May 2024 to Aug 23, 2024
    v4
  4. Primary completion date: May 2026 to Feb 2027
    • Start date: May 2023 to May 2024
    • Study completion date: Jul 2026 to Apr 2027
    • Eligibility criteria expanded, about 23 words
    v3
  5. Start date: Jan 2023 to May 2023
    • Primary completion date: Jan 2026 to May 2026
    • Study completion date: Mar 2026 to Jul 2026
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)
Trial Details
NCT Number NCT05583071
Lead Sponsor University of Cologne
Collaborators: Incyte Corporation
Conditions
(from sponsor)		 Non-Hodgkin Lymphoma
Related terms Lymphoma, Non-Hodgkin
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov